经皮左心耳封堵 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

文章摘要

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial
Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week
Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
Left atrial appendage occlusion in atrial fibrillation patients with previous intracranial bleeding: A national multicenter study
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Atrial Fibrillation: JACC Council Perspectives

Clinical Trial

2019 May 14;40(19):1553-1562.

JOURNAL：Eur Heart J.

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

Oldgren J, Steg PG, Hohnloser SH et al.

9416

Keywords: atrial fibrillation with PCI history; dabigatran with P2Y12 inhibitor vs warfarin with P2Y12 inhibitor and aspirin; major bleeding

FULL TEXT PDF